Skysis, LLC, a specialized consulting firm that provides in-depth strategic insights and commercial execution to biopharmaceutical companies, has added Kevin Weber to its team.

Weber has more than 30 years of commercialization experience, with particular strengths in areas such as product marketing, brand management, commercial/launch planning, positioning and key opinion leader development. He has deep experience in a wide variety of therapeutic areas including pain management, clinical and aesthetic dermatology, inborn errors of metabolism, and respiratory medicine. His previous experience includes executive roles with Depomed, Hyperion Therapeutics, Ucyclyd Pharma and Medicis. In addition to his executive career, Kevin serves on the Supervisory Board of German dermatology company, Biofrontera AG. He is also an active Board member of the American Chronic Pain Association and previously served on the Board of Directors of the American Academy of Pain Medicine Foundation and the Arizona Bioindustry Association.

“We’re excited to have Kevin join the Skysis team,” said Dan Twibell, Skysis Managing Director. “He has deep commercialization experience, as well as a strong understanding of international markets, and clients will benefit greatly from his knowledge and expertise.”

Weber will be based in the company’s Scottsdale, Arizona office.

About Skysis, LLC

Skysis is a team of experienced commercial professionals that provides in-depth strategic insights and commercial execution to biopharmaceutical companies. Through proven processes and an extensive network of subject matter experts, Skysis delivers specialized capabilities in the areas of New Product Planning, Global Pricing & Market Access, Strategic Advisory Services, Market Research and Brand Management. Skysis has more than 85 professionals in the US with a footprint and capabilities that extend across Europe and Asia/Pac. The company’s mission is to partner with its clients to help them achieve a higher level of success.